Zika immune globulin treatment trial launches
Yesterday Emergent BioSolutions announced the start of a phase 1 clinical trial for ZIKV-IG, the company's anti-Zika virus immune globulin. The double-blind, randomized, and placebo-controlled clinical study will enroll about 30 healthy volunteers at a single site.
The US Food and Drug Administration (FDA) granted fast-track designation to ZIKA IG in December of 2017. ZIKA-IG is a purified human immunoglobulin which contains Zika-neutralizing antibodies. Emergent BioSolutions has applied similar immunoglobulin and antibody technology to products aimed at treating anthrax bacteria and vaccinia virus.
"Our program, initiated in 2017, seeks to accelerate development of a Zika-specific immune globulin that leverages our proven platform technology, four decades of patient experience with hyperimmunes, and core competencies in advanced development and manufacturing," said Laura Saward, PhD, senior vice president and antibody therapeutics business unit head at Emergent BioSolutions in a press release.
Jul 31 Emergent BioSolutions press release
Third case of H9N2 reported in China
A woman from Shenzhen is the third human case of H9N2 avian influenza recorded in China this year, according to Avian Flu Diary (AFD), an infectious disease news blog. The blog published a translated notice of the case from Macao's Government Information Bureau.
Officials in Guandong Province confirmed the case in a 24-year-old woman who was hospitalized on Jul 23 after symptoms began 2 days earlier.
There is no mention of poultry exposure in the case notice, but most cases of H9N2 occur after human-bird contact, and most resolve after mild illness. The two cases reported earlier this year involved a child from Guangdong province and a woman Beijing.